Last updated July 17, 2026
Key finding
Patients who received FDGL demonstrated a significant increase in MCV at 3 and 6-month follow-up (p < 0.001).
This study evaluated the efficacy of fermented deglycyrrhizinated licorice (FDGL) in treating early-stage diabetic polyneuropathy, showing significant improvements in nerve conduction velocities and vibration perception.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy of fermented deglycyrrhizinated licorice (FDGL) in treating early-stage diabetic polyneuropathy, showing significant improvements in nerve conduction velocities and vibration perception.
These findings suggest that FDGL could be a beneficial treatment option for individuals with early-stage diabetic polyneuropathy, potentially improving quality of life by alleviating symptoms associated with nerve damage. The significant improvements in nerve conduction velocities indicate a promising avenue for further research and clinical application.
Limited sample size may affect generalizability. Short follow-up duration may not capture long-term effects. No assessment of potential side effects of FDGL.
Published in
Publication details and source links for this paper.
Ahmad MAM, Hoda MAM, Ahmed AE, Mahmoud IE. Efficacy of Fermented Deglycyrrhizinated Licorice in Treating Early-Stage Diabetic Polyneuropathy. Endocrine. 2026;91(1):51. doi:10.1007/s12020-025-04476-5
FDGL increased motor nerve conduction velocity by 1.49 m/s (p < 0.001).
FDGL increased sensory nerve conduction velocity by 3.87 m/s (p < 0.001).
FDGL reduced vibration perception threshold by 7.27 V (p < 0.001).
FDGL increased serum amylase levels by 20.74 IU/L (p < 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to FDGL capsules and Change in motor nerve conduction velocity (MCV) from baseline, Change in sensory nerve conduction velocity from baseline, Change in vibration perception threshold, and 2 more.
This study contributes evidence to
Primary intervention
FDGL capsules
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
5
Evidence pairs
310
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
FDGL capsules → Change in motor nerve conduction velocity (MCV) from baseline
FDGL capsules → Change in motor nerve conduction velocity (MCV) from baseline
FDGL capsules → Change in sensory nerve conduction velocity from baseline
FDGL capsules → Change in sensory nerve conduction velocity from baseline
FDGL capsules → Change in vibration perception threshold
FDGL capsules → Change in vibration perception threshold
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on FDGL capsules and HbA1c, FDGL capsules and Change in motor nerve conduction velocity (MCV) from baseline.
This study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Curated evidence collections and hubs this study is part of.
All studies measuring Change in motor nerve conduction velocity (MCV) from baseline
Measures Change in motor nerve conduction velocity (MCV) from baseline as a key outcome.
All studies on FDGL capsules
Contributes to FDGL capsules evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
FDGL capsules appears to improve Change in motor nerve conduction velocity (MCV) from baseline.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in motor nerve conduction velocity (MCV) from baseline
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
FDGL capsules appears to improve Change in sensory nerve conduction velocity from baseline.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in sensory nerve conduction velocity from baseline
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
FDGL capsules appears to improve Change in vibration perception threshold.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in vibration perception threshold
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
FDGL capsules appears to improve Serum Amylase Levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Serum Amylase Levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
